The European Innovation Council (EIC) is joining forces with German Entrepreneurship to introduce you to some of the most exciting healthcare projects in the EIC Portfolio. Join the EIC & German Entrepreneurship Healthcare Investor Day, on 19 June, 11:00 CEST, to attend pitching sessions, book one-to-one meetings and discover some of the best investment opportunities in European healthcare.
Looking for an extra reason to come to Munich this summer? With health-focused investors already planning their trips to the city for Bits & Pretzels and other exciting events, it’s time to add the EIC & German Entrepreneurship Healthcare Investor Day to your calendar.
Save the date to hear from a curated list of EIC Health innovators, in an event organized in collaboration with German Entrepreneurship on 19 June, 11:00 CEST at their Munich premises in Balanstr. 73 | Haus 19B/EG, 81541.
Sign up for the event.
Applications are open until 1 June.
Who can join?
The EIC is looking for qualified investors active in the Health field, such as Venture Capitalists, Corporate VCs, Family Offices, Angel Investors, etc.
Don’t forget to sign up for the EIC Co-Investment Platform to make the most of the event and find exciting new opportunities.
Which companies will participate?
The EIC portfolio features innovators working on Medtech, new therapeutics, pharma, neurotech and diagnosis, among many other Health solutions.
The final list of pitching companies was selected by a panel of top-level jury members, including investors from APEX Ventures, Armilar Venture Partners, Bullnet Capital, Blue Ribbon Partners, CDP Venture Capital sgr, Coparion, Earlybird Venture Capital, EQT Life Sciences, Hadean Ventures, Heal Capital, High-Tech Gründerfonds, imec.xpand, MIG AG, M-Ventures, Norgine ventures, Omnes Capital, Panakès Partners, TVM Life Science Management GmbH and Voima Ventures Oy. Investors from Ship2B Ventures and Bayern Kapital will also join the event.
Session 1 – Biotech
Allero Therapeutics
Allero Therapeutics is a platform biopharmaceutical company that is focused on the discovery and clinical development of immunotherapies and providing a cure for patients suffering from these diseases, with a lead product in Celiac Disease (CD) that will enter into a large clinical study in 2024. Their core business activity is to apply our SOMIT technology to the treatment of autoimmune diseases and other immune disorders (e.g. allergies), with CD as its first indication. The goal is to restore normal immune balance, avoiding global immune suppression, and treating the underlying cause of the disease.
They are on a Series A funding round, raising €10 million.
Arctic Therapeutics
Artic Therapeutics leverages over 20 years of genomics research to guide its drug discovery, applying bioinformatic approaches and AI to eliminate major risks associated with traditional development, sharply reducing the enormous cost and time to bring effective treatments to millions of patients.
They are on a Series A funding round, raising €5 to €10 million.
Hemispherian AS
Hemispherian is developing a novel type of cancer therapeutics targeting the DNA damage response. These drugs are not only highly effective at targeting cancer cells, but also demonstrate exceptional tolerability with minimal side effects.
They are on a Series A funding round, raising €30 million.
Ovagen Group Ltd
Ovagen is an innovation-based biotechnology company led by experienced entrepreneurs. It has produced the world's 1st germ free (GF) eggs, a novel, ground breaking & disruptive technology to revolutionize global egg based vaccine manufacture. In excess of 1Bn eggs are used annually with up to 30% contamination resulting in serious cost implications and delays to market. GF eggs solve this industry problem.
They are on a Series A funding round, raising €7.5 million.
SOMAprobes SL and Theralia AB
SOMAprobes SL, a Spain-based company, and Theralia AB, a Sweden-based company, are utilizing nucleases as biomarkers in the development of diagnostic devices and therapeutic drugs based on oligonucleotide substrates. By targeting nucleases, which are enzymes that break down nucleic acids, SOMAprobes and Theralia are able to diagnose disease states at the molecular level, and develop precision therapeutics.
They are on a Seed funding round, raising €4 million.
Sequentia Biotech
Sequentia Biotech is a leading omics company that offers advanced bioinformatic solutions to transform omics data into clinical, industrial and research applications. Sequentia has 10 years of expertise in the bioinformatics sector and has delivered more than 500 bioinformatics projects for clients in 62 countries. The company's strong scientific background, with more than 70 publications in top Journals and a cumulative H-index of 130, has granted them the recognition of being in the top 10 companies in digital healthcare in Catalonia, and top 20 global RNA companies for personalised medicine.
They are on a Series A funding round, raising €4 million.
Palobiopharma
Palobiofarma is a Spanish biotech company founded in 2015 to discover and develop novel drugs based on the modulation of the adenosine receptors. The company has progressed to Phase II clinical trials six different compounds targeting therapeutic indications of high unmet medical need.
They are on a Series B funding round, raising €30 million.
Session 2 - MedTech
AI4MED Imaging
AI4MedImaging is a DeepTech company that specializes in developing AI solutions for the automatic analysis of medical imaging. Its flagship product, Ai4CMR, performs a fully automatic segmentation and interpretation of cardiac magnetic resonance exams, making it faster and easier to report these valuable diagnostic exams. Compared to other solutions in the market, Ai4CMR offers unique value propositions such as fully automatic post-processing without any human interaction, detection of pathological findings, and the ability to integrate into existing viewers to facilitate workflow. The product works in the background in the cloud and is cleared by CE-MDR and the FDA (510k).
They are on a Series A funding round, raising €3 million.
Aortyx
Aortyx is developing a disruptive family of endovascular bioresorbable patches to treat aortic diseases, inserted through the femoral artery using a proprietary delivery system. Unlike our competitors, our solution mimics the biomechanical properties of the intervened tissue to secure biointegration. Using a minimally invasive approach, we aim to drastically reduce the mortality and morbidity associated to aortic diseases.
They are on a Series A funding round, raising €12 million.
BOYDSense
BOYDSense’s mission is to democratize health monitoring to improve people's life. BOYDSense is a French startup that develops a breath analysis platform relying on metabolomics and gas sensing technologies. By measuring volatile organic compounds (VOCs) in exhaled breath and leveraging the correlation with blood biomarkers, the miniaturized breath analyzer will provide useful and real-time information to monitor health. The first product/application in development named “Lassie” is dedicated to diabetes.
Dermagnostix GmbH
Dermagnostix is a medtech company that develops, manufactures and markets fully automated, moleculardiagnostic tests for unmet clinical needs in dermatology. With PsorX-LabDisk (CE-IVD), Dermagnostix launches the first molecular test to support the differential diagnosis of psoriasis and eczema. PsorX can be performed my minimally trained users in a self-contained mini-lab, at the point-of-need.
They are on a Series A funding round, raising €10 million.
Tada Group AB
Tada Group AB is a Swedish medical device company, that has solved a problem costing healthcare 72 billion euros every year in unnecessary healthcare consumption and wastes million of nursing hours. Their solution to the global healthcare problem of accidental IV dislodgement is their breakaway connector ReLink. ReLink is specially engineered to enhance infusion stability by keeping the connections between patient and IV catheter, with a controlled break away and predictable results, thereby providing increased safety for patients and nurses across the globe. The first products are shipped to paying customers in May 2023. The company is fundraising to scale production to handle the global demand of ReLink.
They are on a Series A funding round, raising €10 million.
Session 3 - E-Health
enGenome
enGenome was founded in 2016 to enhance healthcare with advanced genomics and its SaaS product eVai represents a breakthrough technology finally able to interpret monogenic, digenic and oligogenic variants.
eVai combines AI and bioinformatics to assess the pathogenicity of single and multiple genomic variants with accuracy and speed, thus drastically increasing the diagnostic yield of genetic testing for hereditary diseases.
They are on a Series A funding round, raising €2 million.
GrayMatters Health Ltd.
GrayMatters Health developed Prism for PTSD, FDA cleared non-invasive, prescription device with biomarkers generated fusing EEG & amygdala-fMRI data, to train PTSD patients regain control over brain mechanisms associated with PTSD. Therapy is covered by existing codes. GMH is expanding to more disorders (e.g. depression) & tx prediction, and received multiple awards globally. GMH is also collaborating with leading institutions and companies such as McLean Hospital (Harvard), NYU Langone, Charite Berlin, Mainz University, Otsuka Japan, and more.
They are on a Series B funding round, raising $5 million.
HumanITcare
HumanITcare's mission is to radically improve people's access to healthcare using AI. They are achieving this by monitoring the health of millions of patients from home with the next generation of solutions to remotely monitor patients being hardware agnostic. They are currently working with more than 20 hospitals, clinics, and healthcare insurance in the EU, and soon the US (2023).
They are on a Series A funding round, raising €5 million.
Methinks AI
Methinks AI's vision is to provide universal and timely diagnosis for life-saving treatments worldwide. Their first focus is on stroke, the major cause of disability and second cause of death. Their CE Mark product is the first AI capable of reducing time-to-treatment up to 60 minutes.
They are on a Series A funding round, raising €5 million.
About German Enterpreneurship
As a valued partner to startups, corporations, universities and public organizations, German Entrepreneurship shapes the future by empowering innovation. Targeted programs like German Accelerator, Scaler8, the EU-India Innocenter, Master Accelerator and Scale-up.NRW address European and international startups as they transition into the world’s most thriving economies. Since 2008, the German Entrepreneurship team has guided more than 750 startups with its global network of experts - including German unicorns like Flixbus and Celonis. Over 500 innovation projects, ranging from innovation coaching to corporate accelerators, were successfully completed on behalf of DAX-listed and medium-sized enterprises. German Entrepreneurship has offices in Munich, Berlin, Düsseldorf, Singapore, Tokyo, Silicon Valley, Boston and New York, and operates with close partners located in India and South Korea.
About the EIC Ecosystem Partnerships and Co-Investment Support Programme
The Ecosystem Partnerships and Co-Investment Support Programme is expanding the EIC’s Business Acceleration Services (BAS) by creating a network of specialized, sector-focused partners that can help innovators access the services they need. It is also dedicated to promoting co-investment along with the EIC Fund, by preparing beneficiaries to interact with investors and connecting them through matchmaking and dedicated events.
Should you have any questions regarding the event, please contact us through the email events@eicfund.eu.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.